Kiniksa Pharmaceuticals, Ltd. (KNSA)
NASDAQ
Healthcare
Biotechnology
$48.70
▼ -0.69%
Market Cap
$3.66B
Sector
Healthcare
Industry
Biotechnology
Beta
0.12
52-Wk Range
26.27-59.87
CEO
Sanj K. Patel
Country
US
Currency
USD
Kiniksa Pharmaceuticals, Ltd. is a global biopharmaceutical firm dedicated to discovering, acquiring, advancing, and commercializing medical therapies for individuals suffering from severe illnesses where current treatment options are insufficient. Its pipeline of potential treatments includes ARCALYST, an interleukin-1alpha and interleukin-1beta inhibitor, aimed at addressing recurrent pericarditis, an inflammatory heart condition. Also in development is Mavrilimumab, a monoclonal antibody inhibitor that has successfully concluded Phase II clinical trials for managing giant cell arteritis. Ad…
Open full interactive analysis & DCF →